The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

Q4 2025 Management View President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five ...

The cystinosis treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough th ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, ...

Six months after Amgen closed its nearly $28 billion acquisition of Horizon Therapeutics, the pharma giant is banking on the rare disease pipeline scored in the deal to buoy its long-term growth. In a ...

Prior to the U.S. Federal Trade Commission's challenge to Amgen's $27.8 billion attempt to acquire Horizon Therapeutics, it had been more than a decade since the agency had challenged a merger in ...

Horizon Therapeutics stock jumped up on the news that the company is in talks to be bought out. The stock closed at $78.76 and opened the next day at $102.65, a 30% gain.

Amgen is spending more than $26 billion to dive deeper into rare-disease treatments with the acquisition of drugmaker Horizon Therapeutics.. The biotech drug developer said Monday that it will pay ...

According to financial terms announced Monday, Amgen will pay $116.50 cash for each share of Horizon. That price represents a 19.7% premium to Horizon’s closing stock price on Friday and a 47.9% ...

Horizon, based in Dublin, has 12 marketed medicines and a pipeline with more than 20 development programs, ... agreed to buy Ireland-based Horizon Therapeutics plc for $28.3 billion in a cash offer.

Shares of Horizon surged nearly 15% to $111.70 in mid-morning trading, while Amgen dropped 1.2% to $275.44. Horizon is based in Ireland, but trades in New York. Responding to an article in The Wall ...

Amgen is acquiring Horizon Therapeutics for $27.8 billion. The deal immediately adds $3.7 billion in annual revenue. The pipeline should be worth it, with the usual risks. Amgen is a large-cap ...